Eiger BioPharmaceuticals, Inc. Stock News

PALO ALTO, Calif., April 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of target

PALO ALTO, Calif., April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of thera

PALO ALTO, Calif., March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of f

EIGR just got approval for progeria. The stock didn't improve much probably because progeria is a minuscule market.

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg a

Eiger is solely focused on rare disease opportunities with its big target being hepatitis delta virus. Eiger's first therapy Zokinvy just got approved which nets the company an important Priority Revi

PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare di

The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processing-defi

PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare di

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Potential Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shareholders may wish to note that the Founder, Jeffrey Glenn...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for sec